top of page
  • Writer's pictureA2A Pharma

A2A Pharma 2nd Quarter Update

Updated: Feb 7, 2020

Update for 2018


39 views0 comments

Recent Posts

See All

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of

Dr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE

bottom of page